00874.HK
Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 12.86
+2.14%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 77.8B | 77.7B | 75.0B | 75.5B | 70.8B |
| Cost of Revenue | 66.3B | 65.0B | 62.5B | 61.3B | 57.5B |
| Gross Profit | 11.5B | 12.5B | 12.5B | 14.2B | 13.3B |
| Operating Expenses | |||||
| R&D Expense | 784.6M | 591.9M | 763.8M | 782.1M | 819.5M |
| SG&A Expense | 8.0B | 3.1B | 3.0B | 6.7B | 6.4B |
| General & Admin Expense | 1.6B | 572.8M | 568.2M | 604.6M | 553.4M |
| Selling & Marketing Expense | 1.1B | 2.6B | 2.4B | 6.1B | 5.9B |
| Other Expenses | 293.1M | 5.2B | 5.2B | (318.0M) | 1.5B |
| Total Operating Expenses | 9.1B | 8.9B | 8.9B | 9.1B | 8.7B |
| Cost and Expenses | 75.4B | 74.0B | 71.4B | 70.4B | 66.2B |
| Operating Income (EBIT) | 2.4B | 3.6B | 3.6B | 5.1B | 5.1B |
| Non-Operating | |||||
| Interest Income | 502.7M | 638.3M | 404.3M | 462.4M | 626.8M |
| Interest Expense | 411.7M | 415.9M | 418.2M | 446.2M | 434.4M |
| Net Interest Income | 91.1M | 222.3M | (35.1M) | 16.2M | 173.6M |
| Other Non-Op Income/Expense | 278.1M | 61.1M | 11.2M | (10.4M) | (31.2M) |
| Non-Operating Income (excl Interest) | (61.5M) | 426.2M | (429.3M) | (435.8M) | (403.3M) |
| EBT (Pre-Tax Income) | 2.7B | 3.7B | 3.6B | 5.1B | 5.0B |
| Income Tax Expense | 463.2M | 629.2M | 606.8M | 851.2M | 789.9M |
| Bottom Line | |||||
| Net Income | 2.2B | 3.0B | 2.8B | 4.1B | 4.0B |
| Earnings from Cont. Ops | 2.2B | 3.1B | 3.0B | 4.3B | 4.3B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 2.2B | 3.0B | 2.8B | 4.1B | 4.0B |
| Per Share | |||||
| Basic EPS | HK$1.33 | HK$1.83 | HK$1.74 | HK$2.49 | HK$2.44 |
| Diluted EPS | HK$1.33 | HK$1.83 | HK$1.74 | HK$2.49 | HK$2.44 |
| Revenue Per Share | HK$47.86 | HK$47.77 | HK$46.13 | HK$46.45 | HK$43.55 |
| Shares | |||||
| Basic Shares Outstanding | 1.6B | 1.6B | 1.6B | 1.6B | 1.6B |
| Diluted Shares Outstanding | 1.6B | 1.6B | 1.6B | 1.6B | 1.6B |
| Profitability Metrics | |||||
| EBITDA | 3.1B | 4.0B | 4.9B | 6.5B | 6.2B |
| D&A | 721.9M | 931.1M | 875.2M | 929.4M | 743.8M |
| EBIT | 2.4B | 3.0B | 4.0B | 5.6B | 5.5B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026